Eli Lilly and Companyand Livongo Health, a consumer digital health company focused on empowering all people with chronic conditions to live better and healthier lives has teamed up on a new strategic collaboration to study real-world evidence and develop new insights to reduce the burden on people living with diabetes.The research collaboration will combine real-world behavioral studies and claims data to advance knowledge about effective interventions in diabetes care. The companies aim to
Read More
type 1 diabetes
JDRF Launches Initiative Encouraging Manufacturers to Build ‘Open’ Diabetes Devices
JDRF, a global organization funding type 1 diabetes research has announced a new initiative that will support the development of 'open' diabetes devices. The initiative is focused on making sure diabetes device manufacturers build management tools – such as continuous glucose monitors and insulin pumps – that can connect with others and give people the option to “hack” their own devices and create an automated insulin delivery system. JDRF believes that both proprietary and open-protocol
Read More
Novo Nordisk & Glooko Launch Integrated Diabetes Management App
Novo Nordisk and Glooko has announced the launch of their new integrated diabetes management app, Cornerstones4Care (C4C app) for patients. The C4C mobile app integrates Novo Nordisk's extensive knowledge of diabetes and personalized patient support with Glooko's digital platform and data analytics expertise. Cornerstones4Care Powered by Glooko AppThe integrated app concept will initially enable people with diabetes to easily measure and track their blood glucose, activity and meals all in one
Read More
Medtronic, Aetna Form Outcomes-Based Partnership for Diabetic Patients
Medtronic, a medical technology provider has entered into a new outcomes-based, risk-sharing agreement with Aetna for type 1 and type 2 diabetes patients currently on multiple daily insulin injections for their diabetes management. The agreement will measure health outcomes for a patient with diabetes who transition to Medtronic’s insulin pump therapy that constantly self-adjusts to keep patients’ blood sugar levels in range based on their personalized needs.This outcomes-based, risk-sharing
Read More
